Ideaya Biosciences: Specialist in Precision Oncology Plans First Product Approval!
Reading Time: 3 minutes
Ideaya Biosciences focuses on precision oncology and plans to submit its first FDA product approval with Darovasertib in the second half of 2026. Phase 2/3 study data for Darovasertib show a 58% reduction in the risk of progression for metastatic uveal melanoma. Collaborations with AstraZeneca, Roche, and Pfizer provide growth potential. With a cash reserve of approximately $1 billion, research is funded through 2030. Ideaya Biosciences (IDYA) focuses as a precision medicine oncology company in the clinical research and development...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
